Wave Life Sciences announces submission of CTA for WVE-007

Wave Life Sciences (WVE) announced the submission of its first clinical trial application, CTA, for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small interfering RNA, siRNA, designed to silence Inhibin betaE, INHBE, gene expression, which would induce fat burning (lipolysis) to decrease body weight without impacting muscle mass. Wave expects CTA approval and initiation of the first-in-human study of WVE-007 in the first quarter of 2025. “Our WVE-007 program, which uses Wave’s best-in-class GalNAc-siRNA capabilities with proprietary chemistry, has potential to be dosed once or twice annually and may ultimately be used across the obesity treatment continuum for sustainable weight loss and cardiometabolic risk reduction,” said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences.